A Phase 1, MultiCenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 Administered Orally Twice Weekly for Three Weeks of a Four Week Course or Twice Weekly for Four Weeks of a Four Week Course to Patients With Advanced Solid Tumours

Trial Profile

A Phase 1, MultiCenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 Administered Orally Twice Weekly for Three Weeks of a Four Week Course or Twice Weekly for Four Weeks of a Four Week Course to Patients With Advanced Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs CNF 2024 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Biogen Idec
  • Most Recent Events

    • 20 May 2009 Additional lead trial investigator identified as Chris Storgard as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 06 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top